JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall St set for higher open as Microsoft's results temper some AI jitters
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner seeks new funds after rout - report
- Stocks gain on tech support, US 30-year yield near 2007 high
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
March 16, 2016 4:05 PM EDTVTP-43742 demonstrated statistically significant efficacy and was well tolerated       Â
Company plans to move VTP-43742 forward into 16-week study
Conference call to discuss results at 5:00 p.m. ET, March 16, 2016
James Krueger, M.D., Ph.D.,... More
